Beese Fulmer Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Beese Fulmer Investment Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,748	Closed	-$271K	–	406
2026 Q1	$271K	Buy	+6,748	New	+$145K	0.02%	333

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Beese Fulmer Investment Management's APLS Position: Q2 2026 in Review

Beese Fulmer Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,748 shares — an estimated $271K sold.

Beese Fulmer Investment Management first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $271K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Beese Fulmer Investment Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Beese Fulmer Investment Management sold 6,748 Apellis Pharmaceuticals shares in Q2 2026, an estimated $271K.
Beese Fulmer Investment Management first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Beese Fulmer Investment Management's Apellis Pharmaceuticals position peaked at $271K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Beese Fulmer Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.